CERT Certara

Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024

Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024

RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.

Investors interested in listening to the conference call are required to . It is recommended to register at least one day in advance.

A live and archived webcast of the event will be available on the “Investors” section of the Certara website at .

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Investor Relations Contact:

David Deuchler

Gilmartin Group

Media Contact:

Alyssa Horowitz



EN
09/10/2024

Underlying

CERTCertara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE
Free
CERT CERTARA

Certara to Report Third Quarter 2024 Financial Results on November 6th...

Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to . It is recommended to register at least one day in advance. A live and archived w...

12h / 2m 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTSH Tile Shop Holdi...
PAYC Paycom Software... ... (+13)

InsiderInsights.com Daily Ratings Report: October 8, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
PAYC PAYCOM SOFTWARE INC.
ANGO ANGIODYNAMICS INC.
XFOR X4 PHARMACEUTICALS INC
ZM ZOOM VIDEO COMMUNICATIONS
ETON INC.
CERT ETON PHARMACEUTICALS
BIGZ CERTARA
MRNA BLACKROCK INNOVATION AND GROWTH TST
SES MODERNA
DV INC.
SES AI CORPORATION
DEVRY INC.
10/09/24 October 9, 2024 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Completes Acquisition of Chemaxon

Certara Completes Acquisition of Chemaxon The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has completed the acquisition of Chemaxon. Chemaxon develops leading scientific informatics software products used by the life sciences industry for in-silico research. Certara develops advanced mod...

October 2, 2024 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara’s Simcyp Consortium Celebrates 25th Anniversary

Certara’s Simcyp Consortium Celebrates 25th Anniversary The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and regulatory decisions RADNOR, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announces the celebration of the of the Simcyp® Consortium. The has become a global authority on mechanistic physiologically-based pharmacokinetic (PBPK) modeling and simulation. With m...

September 24, 2024 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing St...

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times RADNOR, Pa., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001. IG...

September 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch